89bio (Nasdaq:ETNB) - Cotización, noticias y análisis

Resumen de acción ETNB

89bio, Inc. es una empresa biofarmacéutica en fase clínica centrada en el desarrollo y la comercialización de terapias para el tratamiento de enfermedades hepáticas y cardiometabólicas.

Acerca de la empresa

ETNB fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 70.19%

Análisis de riesgos

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Se prevé que los beneficios disminuyan un promedio de 9.7% al año durante los próximos 3 años

Los accionistas han sido diluidos en el último año

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Competidores de 89bio, Inc.

Relay Therapeutics

NasdaqGM:RLAY

US$837.6m

Praxis Precision Medicines

NasdaqGS:PRAX

US$856.9m

ALX Oncology Holdings

NasdaqGS:ALXO

US$856.0m

Arcutis Biotherapeutics

NasdaqGS:ARQT

US$926.5m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for 89bio
Historical stock prices
Current Share Price	US$8.71
52 Week High	US$22.93
52 Week Low	US$6.58
Beta	1.03
1 Month Change	-17.36%
3 Month Change	3.08%
1 Year Change	-51.34%
3 Year Change	-59.73%
5 Year Change	n/a
Change since IPO	-58.13%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	ETNB	US Biotechs	Mercado US
7D	-5.5%	0.5%	2.7%
1Y	-51.3%	3.4%	26.0%

Rentabilidad vs. Industria: ETNB obtuvo unos resultados inferiores a los del sector US Biotechs , que el año pasado arrojó un rendimiento del -2.3%.

Rentabilidad vs. Mercado: ETNB obtuvo unos resultados inferiores a los del mercado US, que fue del 24.9% el año pasado.

Volatilidad de los precios

Is ETNB's price volatile compared to industry and market?
ETNB volatility
ETNB Average Weekly Movement	10.4%
Biotechs Industry Average Movement	11.3%
Market Average Movement	6.1%
10% most volatile stocks in US Market	16.5%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de ETNB ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de ETNB (10%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2018	70	Rohan Palekar	www.89bio.com

89bio, Inc. es una empresa biofarmacéutica en fase clínica centrada en el desarrollo y la comercialización de terapias para el tratamiento de enfermedades hepáticas y cardiometabólicas. Su principal candidato a producto es la pegozafermina, un análogo glicoPEGilado del factor de crecimiento de fibroblastos 21 para el tratamiento de la esteatohepatitis no alcohólica; y para el tratamiento de la hipertrigliceridemia grave. La empresa se constituyó en 2018 y tiene su sede en San Francisco, California.

Resumen de fundamentos de 89bio, Inc.

¿Cómo se comparan los beneficios e ingresos de 89bio con su capitalización de mercado?
Estadísticas fundamentales de ETNB
Capitalización bursátil	US$867.50m
Beneficios(TTM)	-US$165.03m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-5.0x

Ratio precio-beneficio (PE)

¿Está ETNB sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de ETNB
Ingresos	US$0
Coste de los ingresos	US$0
Beneficio bruto	US$0
Otros gastos	US$165.03m
Beneficios	-US$165.03m

Últimos beneficios comunicados

Mar 31, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-1.73
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	4.9%

¿Cómo se ha desempeñado ETNB a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción ETNB

Recompensas

Análisis de riesgos

Competidores de 89bio, Inc.

NasdaqGM:RLAY

US$837.6m

NasdaqGS:PRAX

US$856.9m

NasdaqGS:ALXO

US$856.0m

NasdaqGS:ARQT

US$926.5m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

89bio, Inc., Annual General Meeting, May 29, 2024

89bio, Inc. Appoints Martin Babler to Its Board of Directors

89bio, Inc. Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

89Bio, Inc. Announces Initiation of Its Phase 3 Enlighten Program Evaluating the Efficacy and Safety of Pegozafermin in Patients with Metabolic Dysfunction-Associated Steatohepatitis (Mash), Formerly Known as Nonalcoholic Steatohepatitis

89bio, Inc. announced delayed annual 10-K filing

CEO & Director notifies of intention to sell stock

Recent updates

89bio, Inc., Annual General Meeting, May 29, 2024

89bio, Inc. Appoints Martin Babler to Its Board of Directors

89bio, Inc. Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis

89Bio, Inc. Announces Initiation of Its Phase 3 Enlighten Program Evaluating the Efficacy and Safety of Pegozafermin in Patients with Metabolic Dysfunction-Associated Steatohepatitis (Mash), Formerly Known as Nonalcoholic Steatohepatitis

89bio, Inc. announced delayed annual 10-K filing

CEO & Director notifies of intention to sell stock

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $150 million.

89bio, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

89bio, Inc. Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH)

89bio, Inc. Announces New Positive Long-Term Data from the ENLIVEN Phase 2B Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis

89bio, Inc. Announces New Positive Long-Term Data from the ENLIVEN Phase 2B Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis

89Bio Announces Additional Data from the Enliven Phase 2B Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis

Price target decreased by 9.4% to US$33.44

New minor risk - Share price stability

Price target increased by 7.8% to US$37.44

89bio, Inc. Announces Data from the Phase 2B Enliven Trial Evaluating Treatment with Pegozafermin in Patients with Nonalcoholic Steatohepatitis

89bio, Inc. Initiates Phase 3 ENTRUST Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia

Insider notifies of intention to sell stock

Consensus EPS estimates upgraded to US$2.01 loss

Chief Financial Officer notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Price target increased by 34% to US$33.75

Independent Director exercised options and sold US$92k worth of stock

Chief Financial Officer notifies of intention to sell stock

Price target increased to US$24.63

89bio, Inc. Announces Publication of Results of Phase 1B/2A Study of Pegozafermin for the Treatment of NASH in the Lancet Gastroenterology & Hepatology

Consensus forecasts updated

89bio Presents Additional Exploratory Analyses from the Phase 1b/2a NASH Study of Pegozafermin at AASLD The Liver Meeting(R) 2022

89bio Still Has A Chance As NASH Race Heats Up

Consensus forecasts updated

CEO & Director exercised options to buy US$478k worth of stock.

89bio, Inc. Presents Positive Results from Entrigue Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia At European Society of Cardiology Congress 2022

89Bio, Inc. Completes Enrollment in Enliven, the Phase 2B Trial of Pegozafermin for the Treatment of NASH

89bio completes enrollment in phase 2 trial for NASH treatment

89Bio rallies on Deep Track Capital disclosing 10% stake

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $94.492054 million.

89bio, Inc. has completed a Follow-on Equity Offering in the amount of $94.492054 million.

89bio, Inc. Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

89bio, Inc.(NasdaqGM:ETNB) dropped from Russell 2500 Index

Price target decreased to US$45.67

89bio, Inc., Annual General Meeting, Jun 01, 2022

Price target decreased to US$45.67

89bio, Inc. Appoints Edward Morrow Atkinson to the Board

CEO & Director recently bought US$53k worth of stock

89Bio, Inc. Announces Positive Topline Results from an Open-Label Expansion Cohort of 20 Patients in the Phase 1b/2a Trial of Pegozafermin (BIO89-100) for the Treatment of NASH

COO & Chief Business Officer notifies of intention to sell stock

COO & Chief Business Officer exercised options and sold US$102k worth of stock

COO & Chief Business Officer exercised options and sold US$109k worth of stock

COO & Chief Business Officer notifies of intention to sell stock

COO & Chief Business Officer exercised options and sold US$114k worth of stock

Independent Director Anat Naschitz has left the company

89Bio Completes Target Enrollment in Histology Cohort to Evaluate Bio89-100 for the Treatment of Nash

Price target decreased to US$52.50

89bio: Undervalued Contender In Race For First NASH Drug Approval

COO & Chief Business Officer exercised options and sold US$104k worth of stock

CEO & Director recently bought US$118k worth of stock

89bio, Inc.(NasdaqGM:ETNB) dropped from Russell 2500 Growth Index

COO & Chief Business Officer exercised options and sold US$124k worth of stock

89Bio Initiates Phase 2B Enliven Trial of Bio89-100 for the Treatment of Nash